Effects of add-on ramelteon on cognitive impairment in patients with schizophrenia: An open-label pilot trial

Clinical Psychopharmacology and Neuroscience

Volumn 12, Issue 3, 2014, Pages 215-217

  Shirayama, Yukihiko ^a   Takahashi, Michio ^a   Suzuki, Masatoshi ^a   Tsuruoka, Yoshiaki ^a   Sato, Koichi ^a  

^a TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

Author keywords

Ramelteon; Schizophrenia; Verbal learning

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; RAMELTEON;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; DIGIT SPAN DISTRACTION TEST; DRUG EFFECT; GAMBLING; HUMAN; IOWA GAMBLING TASK; LEARNING; OPEN STUDY; OUTPATIENT; PILOT STUDY; PSYCHOLOGIC TEST; REY AUDITORY VERBAL LEARNING TEST; SCHIZOPHRENIA; STROOP TEST; VERBAL FLUENCY TEST; WISCONSIN CARD SORTING TEST;

EID: 84920017715     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2014.12.3.215     Document Type: Article

References (20)

1. Sponheim SR, Jung RE, Seidman LJ, Mesholam-Gately RI, Manoach DS, O'Leary DS, et al. Cognitive deficits in recent-onset and chronic schizophrenia. J Psychiatr Res 2010;44:421-428.
2. Ammari N, Heinrichs RW, Miles AA. An investigation of neurocognitive subtypes in schizophrenia. Schizophr Res 2010;121:32-38.
3. Elvevåg B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000;14:1-21.
4. Green MF. Stimulating the development of drug treatments to improve cognition in schizophrenia. Annu Rev Clin Psychol 2007;3:159-180.
5. Shirayama Y, Obata T, Matsuzawa D, Nonaka H, Kanazawa Y, Yoshitome E, et al. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. Neuroimage 2010;49:2783-2790.
6. Harvey PD, McClure MM. Pharmacological approaches to the management of cognitive dysfunction in schizophrenia. Drugs 2006;66:1465-1473.
7. Kern RS, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;187:312-320.
8. Norris ER, Burke K, Correll JR, Zemanek KJ, Lerman J, Primelo RA, et al. A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder. J Affect Disord 2013;144:141-147.
9. McElroy SL, Winstanley EL, Martens B, Patel NC, Mori N, Moeller D, et al. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. Int Clin Psychopharmacol 2011;26:48-53.
10. Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, et al DELIRIA-J Group. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry 2014;71:397-403.
11. Borba CP, Fan X, Copeland PM, Paiva A, Freudenreich O, Henderson DC. Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. J Clin Psychopharmacol 2011;31:653-658.
12. Zhang L, Zhang HQ, Liang XY, Zhang HF, Zhang T, Liu FE. Melatonin ameliorates cognitive impairment induced by sleep deprivation in rats: role of oxidative stress, BDNF and CaMKII. Behav Brain Res 2013;256:72-81.
13. Lehtinen EK, Ucar E, Glenthøj BY, Oranje B. Effects of melatonin on prepulse inhibition, habituation and sensitization of the human startle reflex in healthy volunteers. Psychiatry Res 2014;216:418-423.
14. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667.
15. Grace AA. Hippocampal dysregulation of dopamine system activity as a pathophysiological basis for psychosis in schizophrenia. Clin Psychopharmacol Neurosci 2010;8:1-9.
16. Fanget F, Claustrat B, Dalery J, Brun J, Terra JL, Marie-Cardine M, et al. Nocturnal plasma melatonin levels in schizophrenic patients. Biol Psychiatry 1989;25:499-501.
17. Monteleone P, Natale M, La Rocca A, Maj M. Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. Neuropsychobiology 1997;36:159-163.
18. Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Eur Neuropsychopharmacol 2008;18:448-454.
19. Bertaina-Anglade V, Drieu-La-Rochelle C, Mocaër E, Seguin L. Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat. Pharmacol Biochem Behav 2011;98:511-517.
20. Larson J, Jessen RE, Uz T, Arslan AD, Kurtuncu M, Imbesi M, et al. Impaired hippocampal long-term potentiation in melatonin MT2 receptor-deficient mice. Neurosci Lett 2006;393:23-26.